SUPER $TOCKS DD and RESEARCH FORUM

[Ardbeg]

$TXTM DD UPDATE

(All DD has been pulled from various posters on iHub and consolidated here... the images have been left out but you can visit the links to each of the posts if you want to read the original DD and see any images that might have been uploaded.)

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=127396489

BIG DD TXTM ACQUISTION

Here is more information to catch everyone up to speed.

PROTEXT MOBILITY INC. ACQUISTION NEW 8-K

News Out!!!...The company is pleased to announced that it has reached an agreement to acquire Plandai Biotechnology South Africa (Plandai SA), a wholly owned subsidiary of Plandai Biotechnolgy, Inc (PLPL). Plandai SA is a biotechnology firm engaged in the research and development of botanical extracts, aimed at treating metabolic disorders, like diabetes & others. The parent company, Plandaí Biotechnology, Inc. is the culmination of over 10 years of R&D in the field of plant extracts with principle holdings including raw materials processing infrastructure, production facilities, farms and land totaling more than 7500 acres, in the province of Mpumalanga, South Africa.

Closing is expected to occur on or around January 2, 2017.

Additional Information about Plandai Biotechnolgy, Inc

Plandaí Biotechnology, Inc. and its subsidiaries develop highly bioavailable extracts. It controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its proprietary Phytofare® extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include cosmeceutical, wellness, anti-aging, pharmaceutical and animal husbandry.

MJ Research Endorsement in South Africa

December 8, 2016

Plandai Biotechnology, Inc. Announces South African Department of Health Endorses Access to Medicinal Cannabis

Roger Baylis-Duffield,
Chairman and Chief Executive Officer of Plandaí Biotechnology, stated, "We are pleased to see this change in the department's stance on medical cannabis and are looking forward to producing and testing our Phytofare® cannabinoid complex in the near future in South Africa.


Phytofare Technology and Exclusive Rights

Plandai Biotechnology, Inc., a producer of highly bioavailable plant extracts for industries including health, wellness, nutriceutical, and pharmaceutical, today announced that it has signed an exclusive agreement with North-West University in Potchefstroom, South Africa, that holds the patents and associated intellectual property associated with the entrapment of compounds in long-chain fatty acids-based nano- and micro-particles, known as Pheroid(R). Under the terms of the world license, Plandai has the exclusive right to use the Pheroid(R) technology with all Phytofare polyene-based extracts, which includes proprietary extracts of most botanical matter, for human and animal use.
The Pheroid(R) technology, developed for a number of applications by Professors Anne Grobler Awie Kotze and Jeanetta du Plessis of North-West University, allows particles to be encapsulated, or entrapped, in different media that can improve absorption through protecting the contents. It is actively used worldwide for industrial and agricultural purposes and has been extensively tested in humans and animals by Professor Grobler where it has shown an ability to significantly increase the level of absorption of the entrapped particles into the bloodstream.
For Plandai's purposes, the technology will enable the company to produce Phytofare topical products with significantly enhanced tissue absorption and oral products that can help Phytofare survive intact on its passage through the digestive tract and into the bloodstream. Once in the bloodstream, human cells perceive the Pheroid(R) material as a biological building block and as a source of energy, allowing them to pass through the cell membrane and, by metabolism of the long chain fatty acids, release the valuable phytonutrients directly to the tissues.

Plandai and FDA have existing relationship

links

https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11750245

http://www.protextm.co

http://www.nasdaq.com/press-release/plandai-biotechnology-inc-announces-south-african-department-of-health-endorses-access-to-medicina-20161208-00205

https://www.accesswire.com/407406/Plandai-Biotechnology-Inc-Announces-License-Agreement-to-Acquire-Nano-and-Micro-Entrapment-Technology

http://www.nutraingredients-usa.com/Manufacturers/FDA-exemption-speeds-release-of-Plandai-s-catechin-supplement


http://investorshub.advfn.com/boards/read_msg.aspx?message_id=127789442

*** 1-11-2017 TXTM ACQUISITION/MERGER NEWS OUT ***

January 11th, 2016 - Protext Mobility Inc. (OTCPINK: TXTM) announced that it has completed the acquisition of Plandaí Biotechnology South Africa (PTY) LTD “Plandaí SA”, a wholly owned subsidiary of Plandaí Biotechnology, Inc., publicly traded under the ticker (PLPL). Plandaí SA is a biotechnology firm engaged in the research and development of botanical extracts, such as green tea, aimed at treating metabolic disorders, including diabetes. The parent company of Plandaí SA, Plandaí Biotechnology, Inc., is the culmination of over 10 years of research and development in the field of plant extracts with principle holdings including raw materials processing, infrastructure, production facilities, farms and land totaling 7500 acres in the province of Mpumalanga, South Africa.

Plandaí SA was established in 2014 by parent company, Plandaí Biotechnology, Inc. to provide a platform for expanding the research of Plandaí’s proprietary Phytofare® extracts into pharmaceutical applications. Phytofare® has been clinically proven in studies to provide ten times greater bioavailability, which is the ability of the body to absorb the nutrients, over generic plant extracts. The first product brought to market, Phytofare® catechin complex, is derived from green tea and contains all eight catechins in a highly absorbable biocompatible structure. Where the parent company, Plandaí Biotechnology, focuses on selling Phytofare® as an ingredient to manufacturers in the nutraceutical industry, Plandaí SA will target the pharmaceutical market with a finished product.

Plandaí SA has the exclusive license and rights to develop, manufacture, and sell all current and future Phytofare® extracts for the pharmaceutical market worldwide. The first targeted product will focus on treating diabetes by regulating blood sugar levels with an expectation of being market ready in the latter half of 2017.

David Lewis, Director of Protext Mobility, commented, “We’re pleased to announce this share exchange with Plandaí SA and we’re confident that this transaction will create exciting new opportunities for the company. Plandaí has a proven track record for delivering high-quality, science-based botanical ingredients that fit perfectly into the bio-pharmaceutical space. With the first human clinical trial set to commence in the first quarter of 2017, we anticipate great things in the coming months.”

Roger Duffield Bio: Mr. Roger Duffield has a significant background in the development and management of start-ups, private and public companies, especially in the United States, Europe and South Africa. His previous contributions in the United States public sector include Klinair Technologies Inc. and Rhombic Inc. relating to energy and hydrocarbon technologies. Through his extensive involvement with research and development programs with a number of academic institutions, including Penn State, University of Southern California, University of Washington, and the University of Limerick, Ireland, he was awarded two honorary Russian doctorates in Natural Sciences from the University of Moscow and Novosibirsk. In 2001 the Foundation for International Services, California recognized a degree in BSc. Chemical Engineering.

In 2001 he co-founded Global Energy Solutions Corporation Limited, Dublin, Ireland, acquired by Plandaí Biotechnology, Inc., and in 2003, the USA-based Research Company, CRS Technologies Inc. Mr. Duffield now

The Company is also pleased to announce the appointment of Mr. Roger Duffield to the role of Chief Executive Officer and Chairman of the Board. Mr Duffield is a seasoned executive, responsible for the massive undertaking and successful development of the 7500 acre Senteeko Estate. Mr.Duffield, is a hands on CEO, currently in South Africa, overseeing the 100,000 square foot factory, and preparing for the upcoming human
clinical trial being conducted by Plandai SA.

heads this group of companies specializing, through private and public investment in the farming and recovery of highly valuable botanical extracts with unique characteristics.

About Plandai Biotechnology SA

Plandai Biotechnology South Africa (Pty) Ltd recently acquired by Protext Mobility, is a South Africa based research company focusing on the development of pharmaceutical applications for botanical drugs. Plandai South Africa has the worldwide exclusive license to develop Phytofare® in botanical drug applications. Phytofare® is a highly bioavailable extract produced from live green tea leaves that has been clinically proven in trials to have ten-times greater bioavailability over generic extract. What this means is that Phytofare® can deliver a therapeutic level of catechins to the system where they remain active for over 24 hours. The Company plans to commence human clinical trials to determine the effectiveness of using Phytofare® catechin complex in regulating insulin levels in Type II Diabetes patients.

For more information, please visit www.protextm.co
About Plandaí Biotechnology, Inc.

Plandaí Biotechnology, Inc (OTC:PLPL). and its subsidiaries develop highly bioavailable extracts. It controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its proprietary Phytofare® extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company’s products include cosmeceutical, wellness, anti-aging, pharmaceutical and animal husbandry.
For more information, please visit http://www.plandaibiotech.com.

CONTACT INFORMATION [e-mail] https://twitter.com/protxtm


http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128023271

Huge Feb 2017 Marijuana Legalization in South Africa in Feb 2017

Thanks for posting this this info as I believe many are still not aware of this important info and how it relates to the new TXTM.

Since Feb 2017 is only a few more days away, this is huge for TXTM and makes the closing of this acquisition filed in an 8-K with the SEC of Plandaí Biotechnology South Africa absolutely huge:
http://ih.advfn.com/p.php?pid=nmona&article=73652133&symbol=TXTM

What you posted is huge and justifies why this acquisition has taken place right now and not later:

Quote:
________________________________________

Huge Marijuana Legalization in South Africa in Feb 2017

TXTM.PLPL.South Africa to legalize MJ FEB 2017

afkinsider.com/135750/south-africa-legalize-medical-marijuana/
________________________________________

For inquiring minds, PLPL trades in the area of .05 per share and is either the Parent Company or the Sister Company of TXTM. The good thing to note is that both are fully reporting companies that file with the SEC. This can be confirmed from their websites below which are linked to one another when you go through each of them separately:

Quote:
________________________________________

PLPL
https://www.otcmarkets.com/stock/PLPL/profile
http://www.plandaibiotech.com/

________________________________________


Quote:
________________________________________

TXTM
https://www.otcmarkets.com/stock/TXTM/profile
http://www.protextm.co/



http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128034168

TXTM/PLPL, Sunkist, USDA, & CDXC:NASDAQ Connection

JPS02, thanks for posting this. The research that you have posted adds to the ”validity” of what we have here with TXTM (PLPL). In my opinion, TXTM is like a OWCP, SGBY, and CGRA all wrapped up into one. The key with TXTM is that they already have the infrastructure in place to do marijuana cultivation, marijuana laboratory, marijuana clinical trials, medical marijuana, etc. because of PLPL being their Parent Company controlling them.

These are some huge agencies and companies that you posted from their website of which they had previously conducted Clinical Trials with of which these Clinical Trials were very successful. Below are the results from the Clinical Trials that were conducted with Sunkist, USDA, and ChromaDex (CDXC:NASDAQ) for those who have not learned of this yet to confirm the legitimacy of the company:

Quote:
________________________________________

http://plandaibiotech.com/research-development.html
A total of forty six patients (74.2%) reported on the second day of taking the medication that they achieved complete or substantial relief when taking the bioflavonoid combination. In comparison only 30% (50.9%) taking ACP’s, the best known palliative obtained similar relief.
________________________________________

Sunkist is a company that I think we all are familiar with that has generated over $1 Billion in Revenues for 6 (six) consecutive years:
https://www.sunkist.com/press-room/sunkist-growers-announces-sixth-straight-billion-dollar-revenue-year-and-second-consecutive-billion-dollar-grower-payment/

https://www.sunkist.com/

ChromaDex trades on the NASDAQ at over $2.80+ per share with an over $109 Million Market Cap:
https://www.chromadex.com/

United States Department of Agriculture (USDA):
https://www.usda.gov/wps/portal/usda/usdahome


Quote:
________________________________________

PLPL
https://www.otcmarkets.com/stock/PLPL/profile
http://www.plandaibiotech.com/

________________________________________


Quote:
________________________________________

TXTM
https://www.otcmarkets.com/stock/TXTM/profile
http://www.protextm.co/

________________________________________

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128001478

Quote:
________________________________________

http://www.plandaibiotech.com/president.html
"With respect to cannabis, we’ve completed the bulk of our science and are now aggressively seeking a legal venue for producingour Phytofare™ Cannabinoid complex and getting it into clinical trials"
________________________________________


Quote:
________________________________________

http://www.plandaibiotech.com/cannabis.html
...With that being said, Plandaí believes that cannabis shows great medical potential. Unfortunately, very little testing has been done in a true, double-blind, controlled human clinical environment. Much of what we know is either anecdotal or backed by small lab-scale studies. We have developed the science that will allow us to produce a highly bioavailable cannabinoid complex. This new product should enable us to deliver a clinical dose of cannabinoids directly to human tissue and, theoretically, even cross the blood-brain barrier, enabling us to treat neuron disorders. ...

...Plandaí is actively working with several government agencies in hopes of being granted permission to commence testing our cannabinoid product. Once this permission is received, it will take us about ninety days to set up an extraction lab and produce the first extract. This extract will then be tested for purity and undergo a full chemical profile. ...

...We believe that favorable clinical trials will eventually pave the way for government acceptance. Especially for products like Plandaí’s which will have no psychoactive effects. Once we reach that point, we will have several decisions to make: Do we produce an extract locally? Do we license the technology to a third party? Do we farm our own product or purchase from a local grower? ...

...The takeaway for our investors is that Plandaí remains committed to conducting ongoing research with a variety of different plants including cannabis and that this research will go forward as fast as the legal climate permits. Until such time, we remain committed to obeying the laws—federal, state, and international—while we continue to champion for changes to those laws and establish industry standards. We have a fiduciary responsibility to our shareholders to ensure that our company is built on a solid foundation of science, ethics, frugality, and adherence to the laws of the land. ...
________________________________________

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128025299

Quote:
________________________________________

ARTIST, with this Huge TXTM/PLPL South Africa Endorsement

TXTM is an investment that is being setup to help an entire country (South Africa). The market is a little slow in seeing it right now, but I think as more is confirmed and learned by more investors, they will see the magnitude of what's being built here. All should read this 8-K below of the Share Exchange Agreement that closed the TXTMacquisition of Plandaí Biotechnology South Africa:
http://ih.advfn.com/p.php?pid=nmona&article=73652133

This is huge in my opinion regarding Plandai Biotechnology (PLPL) since the TXTM portion of the company that is now Plandaí Biotechnology South Africa will be the vehicle used for the Cannabis/Marijuana projects in South Africa.

What you posted below will tie in very well with South Africa legalizing marijuana this coming Feb 2017:
Quote:
________________________________________

Plandai Biotechnology, Inc. Announces South African Department of Health Endorses Access to Medicinal Cannabis / Move may provide an opportunity for Plandai's research to move forward in South Africa
http://www.finanznachrichten.de/nachrichten-2016-12/39399286-plandai-biotechnology-inc-announces-south-african-department-of-health-endorses-access-to-medicinal-cannabis-move-may-provide-an-opportunity-for-p-256.htm

http://www.health.gov.za/

http://www.gov.za/welcome-official-government-online-site
________________________________________

v/r
Sterling
________________________________________

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128031986

Quote:
________________________________________

mymonies, with these significant TXTM thoughts…

I agree with your thoughts. Doing it this way allows for PLPL to not lose or be hit if things don’t work out becauseTXTM will eventually be judged on its own merits whether they sink or swim.

However, if things turn out to be as big as they believe, which is why they went down this path in the first place, thenPLPL will gain twice as much since they are the Parent Company for TXTM.

The difference between most of the MJ stocks versus TXTM is that most of the MJ stocks operate with only having the reach from its single regulated state only. Now, with TXTM, they are operationally structured to have the reach for an entire country. The TXTM position for expansion is far greater in my opinion.

v/r
Sterling
________________________________________

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128032014

Quote:
________________________________________

Key TXTM & PLPL Connecting Variables

Below from the TXTM Investor’s page, the company has very clearly laid out the TXTM & PLPL Connecting Variables:

http://www.protextm.co/investors

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128029230

Stervc with this HUGE validation of TXTM/PLPL Marijuana connection

It is my opinion, that Artist and you have enlightened me to something far greater than I initially thought.

PLPL current CEO Roger Baylis-Duffield, Chairman and Chief Executive Officer, will be taking over TXTM under the new corporate identity and ticker change coming as per the 8k.

JUST HOW BIG A DEAL IS THIS stock ?

How many other companies do we know of, represent the MMJ growing Industry in the nation of South Africa?

FACTS:
In April 2014, Plandaí applied for a research license under the South African Medicines and Related Substances Act No. 101 of 1965 to undertake defined cannabis-related medicinal research; however, the South African Government took no action on this request and the Company halted its development efforts.

HOWEVER.....Due to the Department of Health's revised position and support of the Ambrosini bill, Plandaí's South Africa legal representatives sent a letter on December 5, 2016 to the South African Director-General of Health, requesting clarification on the Department of Health's position on granting research licenses in light of the Dept. of Health's endorsement. Should the Dept. of Health decide to grant research licenses, Plandaí may then move forward with plans to validate and clinically develop its Phytofare® extract in South Africa in conjunction with North West University's Drug Development Platform.

The Company's 2014 Cannabis initiative was focused on the possible development of a cannabis extract utilizing its Phytofare® technology with the objective to design a non-psychoactive, full profile Cannabis complex of all 113 known cannabinoids. The Company's unique extraction process should prohibit the metabolizing of non-psychoactive acid-form cannabinoids (THC-A and THCB), resulting in an extract that could deliver all the potential medical benefits from a full cannabinoid complex without being psychoactive.

Roger Baylis-Duffield, Chairman and Chief Executive Officer of Plandaí Biotechnology, stated, "We are pleased to see this change in the department's stance on medical cannabis and are looking forward to producing and testing our Phytofare® cannabinoid complex in the near future in South Africa. It gives us pleasure in knowing that Dr. Ambrosini's bill is close to being passed even after his death and we hope to continue in his memory with research for which he was so passionate."

About Plandaí Biotechnology, Inc.
Plandaí Biotechnology, Inc. and its subsidiaries develop highly bioavailable extracts. It controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its proprietary Phytofare® extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include cosmeceutical, wellness, anti-aging, pharmaceutical and animal husbandry.